← Leaderboards
Stella Sarraf
Amydis Diagnostics, Inc.
$16,496,188
Attributed
$16,496,188
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.2M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,496,188 · 11
By mechanism
R44$7,765,167 · 4
SB1$6,453,722 · 2
R43$2,277,299 · 5
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposIn VivoDiagnosticTissuesDepositionSymptomsBindingSmall MoleculeDiagnosisLeadDesignRetinaBrainFluorescenceAmyloidS DiseaseDetectionMouse ModelMonitorEarly DiagnosisPropertyReportingPhysiciansDiagnostic Tests
Grant awards (16)
Development of a topical tracer to detect TDP43 in ALS, LATE and FTD retinas for AI-powered disease insights$1,388,697
R44 · FY2025 · AG · contact PI
Use of novel fluorescent tracers to develop a comprehensive retinal biomarker database that maps the heterogeneity of Alzheimer's pathogenesis$1,715,680
SB1 · FY2024 · AG · contact PI
Use of novel fluorescent tracers to develop a comprehensive retinal biomarker database that maps the heterogeneity of Alzheimer's pathogenesis$1,704,372
SB1 · FY2023 · AG · contact PI
Development of an ophthalmic diagnostic probe for cerebral amyloid angiopathy in patients$1,442,787
SB1 · FY2022 · AG · contact PI
Differential diagnosis of Parkinson's and multiple system atrophy in non-human primate models using a novel a-synuclein retinal contrast agent and AI-assisted analytics$900,109
R44 · FY2022 · NS · contact PI
Development of a novel fluorescent tracer for detection of retinal TDP43 in ALS and FTD$458,527
R43 · FY2022 · AG · contact PI
Differential diagnosis of Parkinson's and multiple system atrophy in non-human primate models using a novel a-synuclein retinal contrast agent and AI-assisted analytics$2,077,573
R44 · FY2021 · NS · contact PI
Development of an ophthalmic diagnostic probe for cerebral amyloid angiopathy in patients$1,590,883
SB1 · FY2021 · AG · contact PI
Development of Novel Tau Retinal Tracers for Alzheimer's Disease and other Tauopathies$492,212
R43 · FY2021 · AG · contact PI
Development of a novel ophthalmic probe for cerebral amyloid angiopathy$1,049,456
R44 · FY2020 · AG · contact PI
Development of a novel ophthalmic probe for cerebral amyloid angiopathy$490,250
R44 · FY2019 · AG · contact PI
Development of Novel Prion Disease Diagnostic$408,225
R43 · FY2018 · AG · contact PI
Development of a Novel Diagnostic Probe for Cerebral Amyloid Angiopathy$534,525
R43 · FY2017 · AG · contact PI
Development of an ophthalmic diagnostic probe for neurodegenerativedisorders$211,174
R44 · FY2017 · AG · contact PI
Development of an ophthalmic diagnostic probe for neurodegenerativedisorders$1,647,908
R44 · FY2016 · AG · contact PI
Development of an ophthalmic diagnostic probe for neurodegenerative disorders$383,810
R43 · FY2015 · AG · contact PI